Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | PI4KA | P42356 | 3/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.34 |
| ▸ | XDH | P47989 | 2/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.33 |
| ▸ | PRKDC | P78527 | 3/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9604644 | 0.76 | ADORA2A (0.46) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL21316678 | 0.72 | ADORA2A (0.53) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL756293 | 0.72 | ADORA2A (0.53) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL946620 | 0.71 | ADORA2A (0.56) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL10835442 | 0.71 | ADORA2A (0.37) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL3035399 | 0.69 | ADORA2A (0.42) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL18076190 | 0.63 | ADORA2A (0.56) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL12699730 | 0.61 | ADORA2A (0.55) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL946072 | 0.61 | ADORA2A (0.55) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL15942468 | 0.61 | ADORA2A (0.55) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2008100447-A2 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | ADORA2A 545/4885ADORA1 199/4885PI4KA 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.